GLP-1s: What the Evidence Actually Shows.
Few interventions in metabolic medicine arrive with this much randomised data. Fewer still are this widely misunderstood.
Medications in the GLP-1 class have changed the clinical conversation around metabolic health faster than almost anything in recent memory. Unusually for a widely publicised treatment, they arrived with a substantial body of randomised controlled trial data.
That evidence is worth understanding directly, because both the enthusiasm and the scepticism around these drugs tend to outrun what the trials actually measured.
What these medications are
GLP-1 stands for glucagon-like peptide-1, a hormone the gut releases after eating. GLP-1 receptor agonists are medications that mimic it. Semaglutide acts on the GLP-1 receptor; tirzepatide acts on both the GLP-1 and GIP receptors.
They influence appetite and glucose through several mechanisms at once:
- Slowing gastric emptying, so food remains in the stomach longer.
- Acting on appetite-regulating regions of the brain, reducing hunger and food preoccupation.
- Increasing insulin secretion in a glucose-dependent manner — meaning the effect scales with blood sugar, which is why these drugs carry a lower intrinsic hypoglycaemia risk than insulin.
What the major trials found
Three trial programmes carry most of the weight in current discussion.
Weight outcomes
The STEP programme studied semaglutide 2.4mg weekly for weight management. In STEP 1, participants without diabetes achieved a mean body weight reduction of roughly 15% over 68 weeks, against roughly 2–3% on placebo — both arms alongside lifestyle intervention.
SURMOUNT-1 studied tirzepatide over 72 weeks and reported a mean reduction of approximately 21% at the highest dose. These are large effects by the standards of medical weight management.
Cardiovascular outcomes
SELECT is arguably the more significant trial. It enrolled people with overweight or obesity and established cardiovascular disease but without diabetes, and reported a roughly 20% reduction in major adverse cardiovascular events on semaglutide.
This matters because it moved the conversation past weight as a cosmetic endpoint and toward a hard clinical outcome.
A trial that measures heart attacks and strokes is answering a different, and more important, question than one measuring kilograms.
What the trials do not tell you
An honest reading requires equal attention to the limits.
Weight tends to return after stopping. Extension data indicate that a substantial proportion of lost weight is regained once treatment ends. These medications behave like a long-term treatment for a chronic condition, not a short course. Anyone considering one should plan for that from the outset.
Some of the loss is lean mass. Weight loss from any cause includes both fat and lean tissue. This is a real consideration — particularly with age — and is the clinical argument for pairing treatment with adequate protein intake and resistance training rather than relying on the medication alone.
Gastrointestinal side effects are common. Nausea, vomiting, diarrhoea and constipation occur frequently, are usually dose-related, and are the most common reason people discontinue. Careful dose escalation exists to manage exactly this.
Trial populations are not everyone. Participants were selected, monitored closely, and supported throughout. Results in a trial are not automatically results in ordinary life.
Long-term data are still accumulating. These medications have years of high-quality data behind them, not decades.
Who they are and are not for
These are prescription medications with specific indications, meaningful contraindications and a real side-effect profile. They require medical assessment before starting, dose titration, and ongoing monitoring — including attention to nutrition and muscle mass, not simply the number on a scale.
They are not a shortcut around metabolic health, and they are not a cosmetic product. Used well, within a supervised programme, they are one of the better-evidenced tools available in metabolic medicine. Used casually, they are a way to lose muscle and regain fat.
A note on this article. This is educational information, not medical advice, and it is not a substitute for assessment by a qualified clinician. Nothing here describes a guaranteed outcome. If any of it is relevant to your own health, the useful next step is a consultation where your history, medications and goals can be considered properly.